Mazur G, Wróbel T, Butrym A, Kapelko-Słowik K, Poreba R, Kuliczkowski K
Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Neoplasma. 2007;54(4):285-9.
Acute myeloid leukaemia (AML) is an aggressive malignancy with accumulation of blasts in bone marrow. Myeloblasts can entry into peripheral blood stream and secondary localize in extramedullary sites. The regulation of this process has not been clearly explained so far, but interactions between some chemokines and their specific receptors could be one of the mechanisms responsible for such kind of migration. Monocyte chemoattractant protein 1 (MCP-1/CCL2) is the chemokine which could be involved in this process. The aim of the study was to evaluate plasma level of CCL2 in patients with AML. Plasma samples from 65 adult patients with AML taken before chemotherapy and in complete remission were measured by enzyme linked immunoassay to evaluate CCL2 levels. Control group consisted of 15 healthy subjects. In AML patients mean baseline CCL2 level (+/- SEM standard error of measurement) was significantly higher than in normal control: 365,26 +/- 5,62 pg/ml vs 265,56 +/- 5,48 pg/ml respectively (p<0.01). We demonstrate increased mean CCL2 plasma level in untreated patients with AML. Significantly lower plasma level of CCL2 was observed in patients with M4 and M5 AML subtypes according to FAB classification. In AML group chemotherapy did not reduce CCL2 plasma level.
急性髓系白血病（AML）是一种侵袭性恶性肿瘤，骨髓中存在大量原始细胞聚集。髓母细胞可进入外周血流，并继发于髓外部位。到目前为止，这一过程的调控机制尚未完全阐明，但一些趋化因子与其特异性受体之间的相互作用可能是导致这种迁移的机制之一。单核细胞趋化蛋白1（MCP-1/CCL2）就是可能参与这一过程的趋化因子。本研究旨在评估AML患者血浆中CCL2的水平。采用酶联免疫吸附测定法检测65例成年AML患者化疗前及完全缓解期的血浆样本，以评估CCL2水平。对照组由15名健康受试者组成。AML患者的平均基线CCL2水平（±测量标准误）显著高于正常对照组：分别为365.26±5.62 pg/ml和265.56±5.48 pg/ml（p<0.01）。我们证实未经治疗的AML患者血浆CCL2平均水平升高。根据FAB分类，M4和M5型AML患者的血浆CCL2水平显著降低。在AML组中，化疗并未降低血浆CCL2水平。
